Logo Logo
Switch Language to German

Horn, L.-C.; Mayr, D.; Brambs, C. E.; Einenkel, J.; Sändig, I. and Schierle, K. (2016): Grading gynäkologischer Tumoren. Aktuelle Aspekte. In: Pathologe, Vol. 37, No. 4: pp. 337-351

Full text not available from 'Open Access LMU'.


Histopathological assessment of the tumor grade and cell type is central to the management and prognosis of various gynecological malignancies. Conventional grading systems for squamous carcinomas and adenocarcinomas of the vulva, vagina and cervix are poorly defined. For endometrioid tumors of the female genital tract as well as for mucinous endometrial, ovarian and seromucinous ovarian carcinomas, the 3-tiered FIGO grading system is recommended. For uterine neuroendocrine tumors the grading system of the gastrointestinal counterparts has been adopted. Uterine leiomyosarcomas are not graded. Endometrial stromal sarcomas are divided into low and high grades, based on cellular morphology, immunohistochemical and molecular findings. A chemotherapy response score was established for chemotherapeutically treated high-grade serous pelvic cancer. For non-epithelial ovarian malignancies, only Sertoli-Leydig cell tumors and immature teratomas are graded. At this time molecular profiling has no impact on the grading of tumors of the female genital tract.

Actions (login required)

View Item View Item